Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  Bioscience Valuation's services help me to communicate the value of our business to various stakeholders, including investors.

Dr. Adi Hoess, CEO Affimed

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model


Bioscience Valuation's Market Model
Customers may license Bioscience Valuation's programs for their own use. Bioscience Valuation's Market Model is a user-friendly Excel®-based program that allows to assess a drug's sales potential. Key advantages of Bioscience Valuation's market model are:
  • user-friendliness and enhanced flexibility,
  • ability to stratify patients,
  • the model suggests estimations of potential market share based on the expected efficacy benefit of a drug,
  • predictions of market share are based on advanced mathematical algorithms that consider the likelihood of launch of competing drugs,
  • ability to be combined with a pharmacoeconomic module to estimate cost-effectiveness that enhances its utility and adaptability.

Bioscience Valuation can provide all required inputs to the model and complete commercial assessments for clients who want to take advantage of Bioscience Valuation's resources.

Please contact us for receiving further information, or to order the model.